Medicenna Therapeutics Corp MDNAF

$MDNAF Chisamore is listed again showing Merck HQ continued scientific engagement & sign-off on scientific communication-It is not a casual thing when Merck admits that a drug is working where PD-1 e.g. Keytruda has failed - This is what the ICI-refectory piece is alluding to and that is MASSIVE. Others who weren’t watching will start sniffing around now.

$MDNAF Top 150 designation badge at SITC. Not bad 👍🏼

$MDNAF Abstract Title posted…”Top 150” look cool!!! Abstract #517 Presents Friday, Nov. 6 Top 150 🎗 MDNA11 Demonstrates Clinical Activity as Monotherapy and in Combination with Pembrolizumab in Biomarker-Enriched Gastrointestinal Malignancies, Including ICI-Refractory Disease Presenting Author Andre Mansinho – START Lisbon, ULSSM – Hospital de Santa Maria,Gulbenkian Institute for Molecular Medicine,Faculty of Medicine, University of Lisbon Authors Andre Mansinho, Victoria Atkinson, Philippe Bedard, Pablo Gajate, Jacqueline Brown, Luis Cabezón-Gutiérrez, Austin Duffy, Victor Moreno, Kim Margolin, Przemyslaw Twardowski, Irene Moreno, Hong Shue, Ira Winer, Michael Chisamore, Marc Oliva, Amy Prawira, Fahar Merchant, Rosemina Merchant, William Gwynne, Minh To, Nageatte Ibrahim, Arash Yavari, Melissa Coello, Hussein Tawbi, Sara Coelho, Igor Medic, Tatiana Hernandez-Guerrero, Paolo Ascierto

$MDNAF Resolution passed… If they do a split before the next data dump it’s over boys and girls.

$MDNAF https://ir.medicenna.com/news-releases/news-release-details/medicenna-announces-results-annual-general-and-special-meeting

$IBRX $XLO $CTMX $MDNAF

Cytokines: $IBRX, $XLO, $CTMX, $MDNAF and the control challenge https://www.merlintrader.com/cytokines/

$MDNAF The SciBrunch deal reinforces 2 key points: 1) Deal value has nothing to do with share price. Biopharma transactions are priced on Net Present Value (NPV), SciBrunch is a private coy- no listed shares, yet got a $2B deal. If “share price” were a prerequisite, this transaction could not exist. 2) Preclinical assets are extremely risky &years away from impact. 90% + of preclinicals fail b4 approval. Assuming a perfect clinical path (which never happens), a preclinical drug needs ~8 years to reach market.SciBrunch’s molecule therefore cannot help Merck’s looming $30B Keytruda hole in 2028. It’s simply too early. In contrast: MDNA11 is a mid‑stage, multi‑tumor asset with a defined registration path, a credible shot at AA & a realistic timeline to reach market in 2028–early 2029 — exactly when Merck’s revenue hole arrives. For Merck or any other big pharma, MDNA11 is a derisked asset positioned as an immediate strategic solution, not a distant speculative bet.